2026-04-13T01:54:55Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1888812025-12-05T14:19:39Zcom_2072_1057col_2072_478902col_2072_478917

00925njm 22002777a 4500 dc Tantai, Xinxing author Liu, Yi author Yeo, Yee Hui author Praktiknjo, Michael author Mauro, Ezequiel author Hamaguchi, Yuhei author Engelmann, Cornelius author Zhang, Peng author Jeong, Jae Yoon author Van Vugt, Jeroen Laurens Ad author Xiao, Huijuan author Deng, Huan author Gao, Xu author Ye, Qing author Zhang, Jiayuan author Yang, Longbao author Cai, Yaqin author Liu, Yixin author Liu, Na author Li, Zongfang author Han, Tao author Kaido, Toshimi author Sohn, Joo Hyun author Strassburg, Christian author Berg, Thomas author Trebicka, Jonel author Hsu, Yao Chun author IJzermans, Jan Nicolaas Maria author Wang, Jinhai author Su, Grace L. author Ji, Fanpu author Nguyen, Mindie H. author 2022-09-12T07:24:09Z 2022-09-12T07:24:09Z 2021-11-14 2022-09-07T12:34:50Z The association between sarcopenia and prognosis in patients with cirrhosis remains to be determined. In this study, we aimed to quantify the association between sarcopenia and the risk of mortality in patients with cirrhosis, by sex, underlying liver disease etiology, and severity of hepatic dysfunction.PubMed, Web of Science, EMBASE, and major scientific conference sessions were searched without language restriction through 13 January 2021 with additional manual search of bibliographies of relevant articles. Cohort studies of ?100 patients with cirrhosis and ?12 months of follow-up that evaluated the association between sarcopenia, muscle mass and the risk of mortality were included.22 studies with 6965 patients with cirrhosis were included. The pooled prevalence of sarcopenia in patients with cirrhosis was 37.5% overall (95% CI 32.4%-42.8%), higher in male patients, patients with alcohol associated liver disease (ALD), patients with CTP grade C, and when sarcopenia was defined in patients by lumbar 3- skeletal muscle index (L3-SMI). Sarcopenia was associated with the increased risk of mortality in patients with cirrhosis (adjusted-hazard ratio [aHR] 2.30, 95% CI 2.01-2.63), with similar findings in sensitivity analysis of cirrhosis patients without HCC (aHR 2.35, 95% CI 1.95-2.83) and in subgroup analysis by sex, liver disease etiology, and severity of hepatic dysfunction. The association between quantitative muscle mass index and mortality further supports the poor prognosis for patients with sarcopenia (aHR 0.95, 95% CI 0.93-0.98). There was no significant heterogeneity in all analyses.Sarcopenia was highly and independently associated with higher risk of mortality in patients with cirrhosis.The prevalence of sarcopenia and its association with death in patients with cirrhosis remain unclear. This meta-analysis indicated that sarcopenia affected about one-third of patients with cirrhosis and up to 50% in patients with ALD or Child's class C cirrhosis. Sarcopenia was independently associated with about 2-fold higher risk of mortality in patients with cirrhosis. The mortality rate increased with greater severity or longer period of having sarcopenia. Increasing awareness about the importance of sarcopenia in patients with cirrhosis among stakeholders must be prioritized. Cirrosi hepàtica Malalties musculars Hepatic cirrhosis Muscular Diseases Effect of sarcopenia on survival of patients with cirrhosis: A meta-analysis